Literature DB >> 15588417

Efficacy of engineered liver tissue based on poly-L-lactic acid scaffolds and fetal mouse liver cells cultured with oncostatin M, nicotinamide, and dimethyl sulfoxide.

Jinlan Jiang1, Nobuhiko Kojima, Lei Guo, Katsutoshi Naruse, Masatoshi Makuuchi, Atsushi Miyajima, Weiqun Yan, Yasuyuki Sakai.   

Abstract

To assess the feasibility of liver tissue equivalents based on selective propagation and differentiation of hepatocyte progenitors in three-dimensional (3D) culture, the efficacy of fetal mouse liver cells cultured in poly-L-lactic acid (PLLA) scaffolds in the presence of nicotinamide, dimethyl sulfoxide, and oncostatin M was investigated both in vitro and in vivo. The albumin production of PLLA-cultured fetal mouse liver cells in the presence of these three factors was remarkably enhanced with culture time, and after 4 weeks it attained almost the same production found in adult mouse hepatocytes cultured for 3 days in PLLA scaffolds, based on the unit DNA amount. In addition, implantation of engineered liver tissue based on this in vitro PLLA culture system into the peritoneal cavity of 70% hepatectomized mice showed a remarkably higher presence of albumin-positive engrafted cells 15 days after the operation when compared with fetal mouse liver cells or adult mouse hepatocytes freshly isolated and cultured for 1 day. These results demonstrate that the basic concept regarding the engineering of liver tissue equivalents based on in vitro selective propagation and differentiation of hepatocyte progenitors in 3D biodegradable scaffolds shows promise for future liver tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588417     DOI: 10.1089/ten.2004.10.1577

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  9 in total

1.  Biomaterials for liver tissue engineering.

Authors:  Era Jain; Apeksha Damania; Ashok Kumar
Journal:  Hepatol Int       Date:  2013-12-27       Impact factor: 6.047

2.  Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells.

Authors:  Bruno Sainz; Francis V Chisari
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Enhanced differentiation of adult bone marrow-derived stem cells to liver lineage in aggregate culture.

Authors:  Kartik Subramanian; Derek Jason Owens; Timothy D O'Brien; Catherine M Verfaillie; Wei-Shou Hu
Journal:  Tissue Eng Part A       Date:  2011-06-30       Impact factor: 3.845

4.  Enrichment of hepatocyte-like cells with upregulated metabolic and differentiated function derived from embryonic stem cells using S-NitrosoAcetylPenicillamine.

Authors:  Nripen S Sharma; Eric J Wallenstein; Eric Novik; Tim Maguire; Rene Schloss; Martin L Yarmush
Journal:  Tissue Eng Part C Methods       Date:  2009-06       Impact factor: 3.056

5.  Three-dimensional polymeric systems for cancer cell studies.

Authors:  Feng Xu; Karen J L Burg
Journal:  Cytotechnology       Date:  2007-07-31       Impact factor: 2.058

Review 6.  Graphene-based 3D scaffolds in tissue engineering: fabrication, applications, and future scope in liver tissue engineering.

Authors:  Renu Geetha Bai; Kasturi Muthoosamy; Sivakumar Manickam; Ali Hilal-Alnaqbi
Journal:  Int J Nanomedicine       Date:  2019-07-24

Review 7.  Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction.

Authors:  Ruchi Sharma; Sebastian Greenhough; Claire N Medine; David C Hay
Journal:  J Biomed Biotechnol       Date:  2010-02-08

Review 8.  Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source.

Authors:  Feng Chen; Hua Wang; Jia Xiao
Journal:  Clin Mol Hepatol       Date:  2020-02-27

Review 9.  Cell and Tissue Therapy for the Treatment of Chronic Liver Disease.

Authors:  Yaron Bram; Duc-Huy T Nguyen; Vikas Gupta; Jiwoon Park; Chanel Richardson; Vasuretha Chandar; Robert E Schwartz
Journal:  Annu Rev Biomed Eng       Date:  2021-05-11       Impact factor: 9.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.